Companies
AMGN
AMGEN INC
The excerpt provided does not contain information about Amgen's therapeutic areas, drug modalities, development stages, or lead programs. The text consists entirely of executive compensation disclosures, equity plan details, and administrative governance information from the company's 10-K filing.
$346.25+22.72%1Y
AMGN · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Metastatic Castration-resistant Prostate Cancer
Phase 3Metastatic Castration-resistant Prostate Cancer
Phase 3Melanoma
Phase 3Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 3KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Phase 3Small Cell Lung Cancer (SCLC)
Phase 3Behçet's Disease
Phase 3Juvenile Psoriatic Arthritis
Phase 3Plaque Psoriasis
Phase 3Active Juvenile Psoriatic Arthritis
Phase 3Behçet Disease
Phase 3Vasculitis
Phase 3Metastatic Colorectal Cancer
Phase 3Osteogenesis Imperfecta
Phase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Phase 2Systemic Lupus Erythematosus
Phase 2Active Refractory Rheumatoid Arthritis
Phase 2B Precursor Acute Lymphoblastic Leukemia
Phase 2Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Phase 2Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Phase 2B Cell Precursor Acute Lymphoblastic Leukemia
Phase 3Metastatic Castration-resistant Prostate Cancer
Phase 3Metastatic Castration-resistant Prostate Cancer
Phase 3KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Phase 2Advanced MTAP-null Solid Tumors
Phase 3Metastatic Castration-resistant Prostate Cancer
Phase 3Migraine
Phase 3Migraine
Phase 3Migraine
Phase 3Metastatic Colorectal Cancer
Phase 2Systemic Lupus Erythematosus
Phase 2Active Refractory Rheumatoid Arthritis
Phase 2Neuromyelitis Optica Spectrum Disorder
Phase 3IgG4 Related Disease
Phase 2Generalized Myasthenia Gravis
Phase 3Generalized Myasthenia Gravis
Phase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Phase 3Small Cell Lung Cancer (SCLC)
Phase 3Obstructive Sleep Apnea
Phase 2Type 2 Diabetes Mellitus (T2DM)
Phase 3Obesity
Phase 3Obesity Disease
Phase 3Heart Failure With Preserved Ejection Fraction
Phase 3Heart Failure With Mildly Reduced Ejection Fraction
Phase 3Atherosclerotic Cardiovascular Disease
Phase 2Overweight or Obesity and Elevated Liver Fat
Phase 3Uncontrolled Gout
Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 3Uncontrolled Gout
Phase 3Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3Non-Small Cell Lung Cancer
Phase 3Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Phase 3Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Phase 3Chemotherapy-induced Thrombocytopenia
Phase 3Osteogenesis Imperfecta
Phase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Phase 2KRAS p.G12C Mutant Advanced Solid Tumors
Phase 2Advanced Solid Tumors
Phase 3Metastatic Colorectal Cancer
Phase 3Non-Small Cell Lung Cancer
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 3Small Cell Lung Cancer
Phase 2Relapsed/Refractory Small Cell Lung Cancer
Phase 3Limited Stage Small Cell Lung Cancer
Phase 3Thyroid Eye Disease
Phase 3Small Cell Lung Cancer (SCLC)
Phase 3Metastatic Castration-resistant Prostate Cancer
Phase 2Thyroid Eye Disease
Phase 2KRAS p.G12C Mutant Advanced Solid Tumors
Phase 2Advanced MTAP-null Solid Tumors
Phase 2Primary Sjogren's Disease
Phase 2KRAS p.G12C Mutant Advanced Solid Tumors
Catalyst Calendar
No catalyst events on record for yet. Check back after the next daily ingest.